Production of host cells containing mutiple integrating vectors by serial transduction

Details for Australian Patent Application No. 2005208507 (hide)

Owner Catalent Pharma Solutions, Inc.

Inventors Bremel, Robert D.; Miller, Linda U.; Bleck, Gregory T.

Agent Spruson & Ferguson

Pub. Number AU-B-2005208507

PCT Pub. Number WO2005/072129

Priority 10/759,315 16.01.04 US

Parent 2001271614

Filing date 14 January 2005

Wipo publication date 11 August 2005

Acceptance publication date 4 June 2009

International Classifications

C07K 14/76 (2006.01) Peptides having more than 20 amino acids

C07K 14/02 (2006.01) Peptides having more than 20 amino acids

C07K 16/12 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from bacteria

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 7/04 (2006.01) Viruses, e.g. bacteriophages - Inactivation or attenuation

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/82 (2006.01) Mutation or genetic engineering - for plant cells

C12N 15/85 (2006.01) Mutation or genetic engineering - for animal cells

C12N 15/86 (2006.01) Mutation or genetic engineering - Viral vectors

C12N 15/864 (2006.01) Mutation or genetic engineering - Parvoviral vectors

C12N 15/867 (2006.01) Mutation or genetic engineering - Retroviral vectors

C12P 21/02 (2006.01) Preparation of peptides or proteins - having a known sequence of two or more amino acids, e.g. glutathione

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms

Event Publications

7 September 2006 PCT application entered the National Phase

  PCT publication WO2005/072129 Priority application(s): WO2005/072129

21 May 2009 Alteration of Name

  The name of the applicant has been altered to Catalent Pharma Solutions, Inc.

4 June 2009 Application Accepted

  Published as AU-B-2005208507

1 October 2009 Standard Patent Sealed

17 March 2011 Assignment Registered

  Catalent Pharma Solutions, Inc. The patent has been assigned to Catalent Pharma Solutions, LLC

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005208552-Use of aerosolized antithrombin to treat acute lung injury

2005208501-Method and system for automatically optimizing zone duct damper positions